How to cite this article: Verweij MM, De Knop KJ, Bridts CH, De Clerck LS, Stevens WJ, Ebo DG. P38 mitogenactivated protein kinase signal transduction in the diagnosis and follow up of immunotherapy of wasp venom allergy. Cytometry Part B 2010; 78B: 302–307.
P38 mitogen-activated protein kinase signal transduction in the diagnosis and follow up of immunotherapy of wasp venom allergy†
Article first published online: 7 MAY 2010
Copyright © 2010 International Clinical Cytometry Society
Cytometry Part B: Clinical Cytometry
Volume 78B, Issue 5, pages 302–307, September 2010
How to Cite
Verweij, M. M., De Knop, K. J., Bridts, C. H., De Clerck, L. S., Stevens, W. J. and Ebo, D. G. (2010), P38 mitogen-activated protein kinase signal transduction in the diagnosis and follow up of immunotherapy of wasp venom allergy. Cytometry, 78B: 302–307. doi: 10.1002/cyto.b.20531
- Issue published online: 25 AUG 2010
- Article first published online: 7 MAY 2010
- Manuscript Accepted: 12 APR 2010
- Manuscript Received: 2 DEC 2009
- University of Antwerp (SBO) (Project 2919)
- p38 mitogen-activated protein kinase;
- signal transduction;
- hymenoptera venom
P38 mitogen-activated protein kinase (MAPK) is known to govern IgE-mediated basophil activation. Intracellular phosphorylated p38 MAPK (Pp38 MAPK) in IgE-activated basophils can be quantified flow cytometrically.
To study whether Pp38 MAPK constitutes a potential novel read-out for flow-assisted diagnosis of hymenoptera venom allergy and to investigate whether this marker allows follow-up of successful venom immunotherapy (VIT).
Fifty-two patients with documented wasp venom allergy and seven wasp-stung asymptomatic control individuals were enrolled. Wasp venom-induced basophil activation was analyzed flow cytometrically with anti-IgE, anti-CD63, and anti-Pp38 MAPK to assess their activation status before starting immunotherapy. To assess whether p38 MAPK constitutes a candidate marker for monitoring VIT, we repeated the basophil activation test (BAT) in 25 patients on the fifth day of a build-up immunotherapy. In addition, we investigated whether the Pp38 MAPK-based BAT could contribute in the decision of discontinuing VIT in a cross-sectional analysis in 13 patients receiving treatment for 3 years and 14 patients receiving treatment for 5 years.
Patients exhibited a dose-dependent basophil activation with phosphorylation of p38 MAPK and upregulation of downstream CD63. In contrast, stung controls demonstrated a dose-dependent but “abrogated” signal transduction in basophils with less and shorter duration of the phosphorylation of p38 MAPK and without subsequent upregulation of CD63. When repeated after 5 days of VIT and when investigated cross-sectionally after 3 years or 5 years of maintenance therapy, no effect of VIT on the phosphorylation of p38 MAPK was demonstrable.
This study discloses that not only basophils from patients, but also from the stung control individuals, respond to wasp venom stimulation with phosphorylation of p38 MAPK, although to a lesser extend. No clear effect of VIT on the phosphorylation of p38 MAPK was shown. Thus, although p38 MAPK provides an additional tool in the diagnosis of wasp venom allergy, it does not contribute to the decision whether to stop successful VIT. © 2010 International Clinical Cytometry Society